The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

OBJECTIVE: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The pathways affected by tofacitinib and the effects on gene expression in situ are unknown. Therefore, tofacitinib effects on synovial pathobiology were investigated. METHODS: A randomised...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Ann Rheum Dis
Main Authors: Boyle, D L, Soma, K, Hodge, J, Kavanaugh, A, Mandel, D, Mease, P, Shurmur, R, Singhal, A K, Wei, N, Rosengren, S, Kaplan, I, Krishnaswami, S, Luo, Z, Bradley, J, Firestein, G S
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Publishing Group 2015
Fag:
Basic and Translational Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4431345/
https://ncbi.nlm.nih.gov/pubmed/25398374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2014-206028
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker